Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.
about
Ubiquitin-dependent proteasomal degradation of human liver cytochrome P450 2E1: identification of sites targeted for phosphorylation and ubiquitinationModeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro dataPhysiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycinRevolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells.Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study.The formation and biological significance of N7-guanine adductsHuman liver cytochrome P450 3A4 ubiquitination: molecular recognition by UBC7-gp78 autocrine motility factor receptor and UbcH5a-CHIP-Hsc70-Hsp40 E2-E3 ubiquitin ligase complexesArtemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implicationsEffect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers.Risk assessment of mechanism-based inactivation in drug-drug interactions.Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole.Pharmacokinetic interaction between telaprevir and methadonePrediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic ModelHepatic CYP3A suppression by high concentrations of proteasomal inhibitors: a consequence of endoplasmic reticulum (ER) stress induction, activation of RNA-dependent protein kinase-like ER-bound eukaryotic initiation factor 2alpha (eIF2alpha)-kinaseEffect of Red Ginseng on cytochrome P450 and P-glycoprotein activities in healthy volunteersApplication of mechanism-based CYP inhibition for predicting drug-drug interactions.Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.Hepatic cytochrome P450 ubiquitination: conformational phosphodegrons for E2/E3 recognition?Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound.Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers.Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.CYP3A activity: towards dose adaptation to the individual.Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.Convergence of hepcidin deficiency, systemic iron overloading, heme accumulation, and REV-ERBα/β activation in aryl hydrocarbon receptor-elicited hepatotoxicity.Retrospective use of PBPK modelling to understand a clinical drug-drug interaction between dextromethorphan and GSK1034702.Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions.Physiologically Based Pharmacokinetic Modeling of Palbociclib.Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor.From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example.Semi-mechanistic autoinduction model of midazolam in critically ill patients: population pharmacokinetic analysis.Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?Dexamethasone suppresses the expression of multiple rat carboxylesterases through transcriptional repression: evidence for an involvement of the glucocorticoid receptor.
P2860
Q28302541-B3640D66-7309-4E60-8319-4544B7C2FA78Q28533793-AB6F8AB5-24A9-4DF3-837B-2C6C6D087196Q33613354-48730807-278E-4BE3-A647-EB5D949FA69CQ33649076-331B2050-105C-4DC3-B335-60A5196A51A7Q34742606-BC2D7C0F-A05C-4669-B748-F118474AE109Q34982742-309DA41B-FD5F-4C5D-AC3A-13E868E64B79Q35055500-B0AECAB4-37B9-4794-B127-BE199B35F16EQ35286119-1D31765A-E511-481A-8E24-FA80ABDE657AQ35904433-6F874216-C9CB-4C3F-8F8E-CBA813BED174Q36174265-AC2E0E3F-29BE-4B80-9B93-5D648EEA2283Q36737024-45DA0C92-2A7E-4425-B890-1B3E8480ACB4Q36785929-274E3A4E-6C2C-45AC-9DEA-4D346959DD16Q36947718-B8EA3230-1875-4D8A-B681-CFAD91330D47Q37314375-5B25D8DC-A57B-4D65-A947-A3DECBBCE4BFQ37314453-E94A7AD2-7451-49F6-8372-D06C2015CDCCQ37494640-C73B3BEE-83BC-431C-8691-87C625AFDE47Q37613039-CA04BF0D-CCDC-4117-99DB-F77DDA18277AQ37648157-64D42702-1440-4230-8F6B-E3598843F47FQ37965706-1AFB8945-B77A-4176-A643-D7922D5C9B36Q38014312-B370654A-4530-4C8C-83B2-9E6BE7D81A16Q38087695-C78D2E31-7E17-46D8-9EE3-1F0C85E40344Q38153196-7CCA547E-CF63-4CCA-B39B-89275B9776B1Q38346846-092CD8FC-8611-4433-90DE-1F374A37E9BCQ38621024-1A7916C2-01F1-4650-A880-8579273BEC8FQ38625769-0CF8E111-C561-43B2-B225-9A99F12D1AA4Q38634986-A249FEED-434B-4050-85D3-F1EED52C5837Q38684505-A93A9EE0-0288-4935-9B16-FC4B3BF3230CQ38763583-768C2ADB-33B0-4A6A-945E-F34C8445157FQ38813488-2CEE3D78-D898-40D1-8EC0-37C4210FBBF7Q38836056-AEF39398-8492-443E-A34F-4D3C18C25569Q38954756-276E277C-2928-4FF7-9224-17829AB0D964Q39136867-8C87DE13-BDF0-4736-B420-54A02AAE160AQ39158102-21F026AD-66C6-434F-93F1-540D632BB40DQ39240124-2AC1DE22-6031-4E83-9DF6-B36771298A96Q39612151-C6522A6E-4022-46FB-84C0-4B36DA7689C4Q39643626-BE90356D-6749-450E-891D-628C3A857D05Q39645850-3CA08267-1241-434B-9E1C-06C6D9C28A33Q39767125-C5E810A2-E052-425A-B98C-0C7A3D60034DQ39796487-CD1CC1A4-5574-4A8A-8C17-145F20B93FF6Q39927144-D19E2341-8A4A-4C0D-9907-8C03E6F9E0DE
P2860
Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cytochrome p450 turnover: regu ...... ediction of drug interactions.
@ast
Cytochrome p450 turnover: regu ...... ediction of drug interactions.
@en
Cytochrome p450 turnover: regu ...... ediction of drug interactions.
@nl
type
label
Cytochrome p450 turnover: regu ...... ediction of drug interactions.
@ast
Cytochrome p450 turnover: regu ...... ediction of drug interactions.
@en
Cytochrome p450 turnover: regu ...... ediction of drug interactions.
@nl
prefLabel
Cytochrome p450 turnover: regu ...... ediction of drug interactions.
@ast
Cytochrome p450 turnover: regu ...... ediction of drug interactions.
@en
Cytochrome p450 turnover: regu ...... ediction of drug interactions.
@nl
P2093
P1476
Cytochrome p450 turnover: regu ...... ediction of drug interactions.
@en
P2093
Amin Rostami-Hodjegan
Geoffrey T Tucker
Jiansong Yang
Karen Rowland Yeo
Magang Shou
Masoud Jamei
Mingxiang Liao
P304
P356
10.2174/138920008784746382
P407
P577
2008-06-01T00:00:00Z